Safe Medication for COPD Patients with Urinary Frequency

Introduction to Mirabegron

The European Respiratory Journal recommends avoiding traditional antimuscarinic medications in COPD patients because they can increase respiratory secretions and potentially worsen dyspnea 1
The British Thoracic Society guidelines suggest that adding systemic anticholinergics for bladder control to anticholinergic bronchodilators can compound the secretion burden in COPD patients 2, 1

The British Thoracic Society guidelines already recommend anticholinergic bronchodilators as standard COPD therapy, and mirabegron works through β3-adrenoceptor agonism, eliminating the respiratory concern associated with anticholinergic medications 2, 1
In patients with mild COPD who are not experiencing significant sputum production, antimuscarinics could be cautiously trialed if mirabegron proves ineffective, according to the British Thoracic Society and European Respiratory Journal guidelines 2, 1

The British Thoracic Society guidelines note that beta-blockers should generally be avoided in COPD patients, but if essential for cardiac indications and the patient is taking metoprolol or other CYP2D6 substrates, careful monitoring is required due to significant increases in exposure 2